The turmoil created in the pharmaceuticals' market during the first quarter of 2010 -which continues until today- has significantly affected Lavipharm's Financials. In anticipation of the decrease in drug prices, as expected since the beginning of the year, sales have dropped drastically, due to warehouses...
Consolidated Turnover posted an increase of 5%, reaching Euro 249.8 million compared to Euro 238.0 million during 2008. International Sales have increased by 17%, accounting for 11% of Total Sales. Gross Profit reached Euro 39.5 million from Euro 37.4 million in the last period (+5.6%)....
Profitability and constant growth highlight Lavipharm Group financial results of 9M 2009, maintaining its positive course since the beginning of the year. Consolidated Turnover reached Euro 182,9 million compared to Euro 176,4 million during the 9M of 2008. The significant decrease in operating expenses (-14,9%)...
Lavipharm SA, according to the obligations deriving from 3/347/12.07.2005 of the Capital Market Committee, announces that Mrs. Ioanna Tsireka assumes the responsibility of Human Resources Director at Lavipharm Group replacing Mrs. Helen Markou. Mrs. Markou will continue to contribute to Lavipharm as Management Advisor in...
Consolidated Turnover was formulated at Euro 122,8 million opposed to Euro 119,7 million during the H1 of 2008. The significant retention of operating expenses (-14,0%) improved operating results of the Group, which concluded to profits of Euro 2,6 million opposed to losses of Euro 1,3...
Announcement Lavipharm SA informs the investment community according to article 4.1.4.3.1 of ATHEX Regulation that the Financial Calendar of 2009 is formed as follows: 1. Announcement and release of FY2008 Financial Statements: Tuesday, March 31st, 2009. 2. Presentation to Analysts: Friday, May 15th, 2009. 3. Shareholders General Meeting:...
